Effects of dulaglutide and liraglutide combined with metformin in obese patients with type 2 diabetes mellitus:a comparative study
Objective To compare the effects of dulaglutide and liraglutide combined with metformin on serum C1q/TNF-related protein 3(CTRP3)and vascular cell adhesion molecule 1(VCAM-1)in obese patients with type 2 diabetes mellitus(T2DM).Methods A total of 89 obese T2DM patients who were admitted to Affiliated Nantong Hospital of 3 Nantong University from March 2019 to September 2022 were selected as research subjects.They were randomly divided into liraglutide group(n=45,liraglutide+metformin)and dulaglutide group(n=44,dulaglutide+metformin).Body mass index(BMI),obesity degree,waist circumference,hip circumference,glucolipid metabolism related indexes,insulin resistance related indexes,CTRP3,and VCAM-1 were compared between the two groups.Results Compared with those before treatment,BMI,obesity degree,hip circumference,waist circumference,glucolipid metabolism related indexes,insulin resistance related indexes,CTRP3,and VCAM-1 were significantly changed after treatment(all P<0.05).Mean amplitude of glucose fluctuation(MAGE)and VCAM-1 in the dulaglutide group were significantly lower than those in the liraglutide group after treatment,while time in target glucose range(TIR)and CTRP3 in the dulaglutide group were significantly higher than those in the liraglutide group after treatment(all P<0.05).There was no statistically significant difference in the other indexes between the two groups after treatment(all P>0.05).Conclusion Both dulaglutide and liraglutide combined with metformin can control blood glucose levels and improve glucolipid metabolism in obese T2DM patients.But dulaglutide is more effective in controlling MAGE and TIR than liraglutide,which may be related to the ability of dulaglutide to regulate the levels of CTRP3 and VCAM-1.
NETL
NSTL
万方数据
